Summary
Introduction
In 1995, the Expert Advisory Group on Cancer published the Calman-Hine report, 1 in which they recommended that strategic improvements be made to cancer services in England and Wales. However, no additional resources were provided for the recommended improvements, and implementation of the recommendations was left to local initiative. By 1999, progress in improving cancer services was seen as inadequate. 2 The National Health Service (NHS) cancer plan for England was published in late 2000. 3 It was a comprehensive 10-year strategy, designed to improve prevention, early diagnosis, and screening, and to provide optimal treatment for all patients, thus improving survival and quality of life. An important feature was the creation of multi-disciplinary teams In Wales, the Cancer Services Expert Group recommended substantial changes to cancer services in 1996. 4 Changes included the creation of MDTs and the designation of specialist clinicians, but the approach relied heavily on clinical collaboration, supported by directives from the devolved administration, rather than on a formal strategy. The full national cancer plan for Wales, Designed to Tackle Cancer, 5 was not published until late 2006.
3-year progress reports on the NHS cancer plan were published in October, 2003, 6, 7 when, despite substantial progress, it was acknowledged that it would take time before the eff ects of the plan could be assessed. Here, we have chosen to examine survival trends during two 3-year periods after the introduction of the plan: 2001-03 and 2004-06. Population-based cancer survival serves as a broad measure of the overall eff ectiveness of health services. Survival is generally improving, so to measure the eff ect of the NHS cancer plan we looked for evidence of any acceleration in survival trends. Given the diffi culty of introducing systematic, nationwide changes in the NHS, it would be surprising if survival trends for patients diagnosed in England during 2001-03 were to diff er much from earlier trends as a direct result of the plan. However, for patients diagnosed during 2004-06, at least 3 years after implementation of the plan, any marked improvements in the overall eff ectiveness of cancer services might reasonably be expected to show an eff ect on trends in short-term survival.
Given the later implementation of a strategic cancer plan in Wales, comparison of survival trends in England and Wales over the same calendar periods could be instructive. A cancer plan that was implemented nationwide cannot later be assessed in the same way as a randomised trial. But an observational comparison of outcomes before and after the introduction of a plan in one of two adjacent countries, with similar societies and health systems, seemed to be a reasonable alternative. Similar trends in cancer survival might be expected in both countries up to 2000. But, if the cancer plan were eff ective, we would expect that England would experience a faster improvement in survival than Wales after several years of latency. Up to 7 years of follow-up are available for patients diagnosed since the introduction of the plan. 1-year survival trends might be expected to accelerate more rapidly in successive calendar periods in England than in Wales after the introduction of the plan, if the plan was eff ective. 3-year survival trends might also be diff erent in England and Wales.
On Dec 10, 2008 , the Offi ce for National Statistics (ONS) published the offi cial national statistics on survival for patients diagnosed with one of 21 common cancers in England during 2000-04 and followed up to 2005. 8 National statistics on survival for cancer patients diagnosed in England during 2001-06 and followed up to Dec 31, 2007 , were published on March 20, 2009 . 9 We have used these data, and the data for all cancer patients diagnosed in Wales, to study national and regional trends in survival up to the end of 2007.
Methods

Data collection
Population-based cancer registries collect a small standard dataset for all cancer patients in a defi ned population. Data-collection methods vary between cancer registries, but the main sources of data are hospital in-patient records and pathology records. The National Cancer Registry has collated data from regional cancer registries covering the entire population of England and Wales since 1962. Since 1971, the National Health Service Central Register (NHSCR) has provided notifi cation of the deaths of all cancer patients whose record was successfully fl agged with details of the initial cancer registration.
Data for this study were extracted from the National Cancer Registry at the ONS after the linkage of cancer records with data on the patient's vital status (alive, emigrated, dead, not traced) at NHSCR. After powers to legislate on health policy were devolved to UK national assemblies from 1997, cancer registration in Wales passed to the Welsh Cancer Intelligence and Surveillance Unit, but the National Cancer Registry at the ONS continues to receive cancer data from Wales, and the vital status of all cancer patients in England and Wales is updated by the ONS. When the data were extracted on Oct 17, 2008 , the vital status at Dec 31, 2007 , was known for 99·6% of patients diagnosed with cancer during 1996-2006, without regional variation. The data were received on Dec 15, 2008. Cancers were defi ned by their anatomical location (site), morphology, and behaviour (benign, in situ, or invasive). Tumour site was coded according to the tenth revision of the International Classifi cation of Diseases (ICD-10). 10 Morphology and behaviour were coded according to the second edition of the International Classifi cation of Diseases for Oncology (ICD-O-2). 11 We examined data for 21 common cancers, 17 in men and 18 in women. We analysed survival for laryngeal cancer in men only, and for breast cancer in women only. Data on stage at diagnosis were not available for all patients and could not be usefully incorporated in our analyses. Standard criteria were used to decide whether a tumour record was eligible for inclusion in the analyses. 12 Records were excluded if they contained data of inadequate quality or were for patients not resident in England or Wales. 1·25 million of 8·4 million patients registered with benign tumours (behaviour code 0), tumours of uncertain behaviour (code 1), in-situ neoplasms (code 2) or a metastasis (code 6) were not included. Of 13 We analysed the cancer data for each region, for England as a whole, and separately for Wales.
Statistical analysis
Survival trends were quantifi ed as the year-on-year rate of change within each calendar period. The diff erence in survival trends between successive calendar periods provides a measure of any acceleration (or deceleration) in the rate of change in survival between successive periods. Diff erences or trends are given as the simple arithmetic values; so 12% is reported as 2% (not 20%) higher than 10%, and a rise from 10% to 14% over 4 years is reported as an increase of 1% per year.
We estimated relative survival for England, for Wales, and for the nine government offi ce regions of England, for each cancer, each sex, and by year or period of diagnosis. Relative survival is the ratio of the observed probability of survival and the probability that would have been expected if the cancer patients had only experienced the normal (background) mortality of the general population in which they live, 14, 15 given the same distribution of factors such as age, sex, geographic area, calendar period, and deprivation. Relative survival is the standard approach to estimating population-based survival. It does not rely on accurate reporting of the cause of death, 16 and it enables the estimation of longterm survival from cancer, when competing causes of death become more important. 17 It can be interpreted as survival from cancer after adjustment for other causes of death.
Expected survival is derived from population life tables. Background mortality rates by age and sex diff er widely between socioeconomic groups and geographic regions in England and Wales, 18 and these diff erences have changed over time. We therefore constructed life tables (available online 19 ) of all-cause death rates by single year of age (0-99 years), sex, deprivation category, and government offi ce region for 1991, 2001, and 2005, using the mid-year population estimates and the mean annual number of deaths during the 3 years centred on the index year. Linear interpolation was then used to obtain life tables for each calendar year in the period 1992-2005. Life tables for 2006 and 2007 could not be constructed because the relevant data (deaths during 2007-08) were unavailable, so life tables for 2005 were used for those years without extrapolation. National and regional analyses for England were all done with life tables specifi c for sex, government offi ce region, deprivation category, and calendar year from 1996.
Five deprivation categories were defi ned from quintiles of the income domain score of the indices of multiple deprivation (IMD2004), 20 and the equivalent indices for Wales, 21 using administrative data for the 34 378 lower super-output areas (LSOAs, mean population 1500) 22 in England (2001) and Wales (2002-04). Cancer patients were assigned to the deprivation category of their LSOA, using the postcode of residence at diagnosis and a combined historic fi le of 2·1 million unique full postcodes, each linked to a complete set of geographic area codes for each year that the postcode was active. Death records were assigned to deprivation categories using the postcode and LSOA in the same way as the cancer cases, so that background mortality was precisely matched to the small areas of residence and deprivation categories of the cancer patients. Although socioeconomic inequalities (the socalled deprivation gap) in survival have been widening for many adult cancers in England and Wales, 23 tending to reduce the overall national gain in survival, recent trends in the deprivation gap in survival will be reported separately.
Survival probabilities were estimated at short (for example, 1-month) intervals in the fi rst few months after diagnosis, then at progressively longer intervals up to 10 years after diagnosis, using the maximumlikelihood approach for individual data. 24 We report the cumulative probabilities of relative survival at 1, 3, 5, and 10 years after diagnosis. We also report 5-year survival for patients who survived at least 1 year after their diagnosis (conditional survival).
Given the structure of the data, various analytical approaches were required. The classical (cohort) approach was suitable for the analysis of year-on-year trends in 1-year survival, since all patients were followed up at least that long (fi gure 1). For the period 1996-2000, the cohort approach was used for 5-year survival and the complete approach to estimate 10-year survival. Short-term prediction of survival for patients diagnosed during 2007 was made with the hybrid approach, 25 combining the 1-year survival probability for patients diagnosed during 2006 with the survival probabilities for the second and later years after diagnosis for patients who were alive and followed up for at least part of 2007. Conditional 5-year survival was available with the cohort approach for 1996-2000, the complete approach for 2001-03, and the period approach 26 for 2004-06 (fi gure 1). Year-on-year trends in survival were estimated within a single variance-weighted linear regression 27 model covering all 11 years and each calendar period, including two extra parameters in addition to the baseline trend, to allow for diff erent trends in successive periods. We report the relative survival estimate derived from the regression model for the last year of each calendar period. We report changing survival trends as the absolute diff erence between the regression slopes for each calendar period: a positive value implies acceleration of the upward trend in survival and a negative value implies deceleration (see webappendix). Survival analyses were done with the publicly available Stata program strel. 28 Other analyses were programmed in Stata version 10. 29 We constructed funnel plots 30 to visualise the regional variability of 1-year survival in England and Wales for cancer patients diagnosed during 2004-06. The plots allowed us to estimate how much a particular estimate of survival deviates from the pooled England value (the target), given the precision of each estimate. 1-year relative survival estimates for 2004-06 for each population were plotted against the precision of the estimates, taken as the inverse square of their standard errors. The target value, taken as the estimate of 1-year relative survival pooled across the nine regions of England for all patients diagnosed during 2004-06, is represented by the horizontal line in each plot. Wales was not included in the target value, so that the estimates for Wales could be compared with those for England. The 95% and 99·8% control limits, derived from the complementary log-log transformation of the target estimate for England across the observed range of precision of the regional estimates, 31 represent approximately two and three standard deviations, respectively, from the target value at each level of precision (webappendix). Estimates that lie inside the control limits were considered as within the geographical variation that could be expected by chance. This analytical strategy, including defi nition of the calendar periods, the cancers, life tables, approaches to estimation of survival and survival trends, and the structure of the tables and graphics, was specifi ed in advance, after data preparation was complete but before the start of any analyses. This was done to pre-empt any concerns regarding possible data-dredging in favour of a particular conclusion, whether for or against the eff ectiveness of the NHS cancer plan.
Legal authority to hold the cancer data derives from a contract with the ONS to produce the offi cial national statistics 32 Numbers in the cells indicate the minimum number of years of follow-up completed by patients surviving to the end of a given calendar year (columns) who were diagnosed in the index year (rows). In the cohort approach all patients diagnosed in a given period were followed up for at least 5 years. In the complete approach some patients were followed up for less than 5 years. In the hybrid approach survival is estimated from the most recent follow-up data (dashed lines). Conditional 5-year survival is restricted to those who had survived at least 1 year; ie, excluding follow-up in shaded cells.
See Online for webappendix 
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All patients were aged 15-99 years, were diagnosed from 1996 to 2006, and were followed up until 2007. *Mean annual change (%) in relative survival within each calendar period (absolute value). †Fitted estimate of relative survival for the last year of the calendar period. ‡Diff erence in the year-on-year trends between successive calendar periods. §p<0·01. ¶p<0·05. Pancreas   3  3·9  4·1  5·0  0·0  0·3 ¶  0·1 ¶  5·1  3·4  3·9  4·1  0·1  0·1  0·1 ¶  4·4   5  2·9  2·8  ··  0·0  ··  ··  3·7  2·3  2·7  ··  0·1  ··  ··  3·2   5 (conditional) 20·1  18·4  ··  -0·4  ··  ··  22·1  18·4  19·3  ··  0·2  ··  ··  19·6   10  2·2  ··  ··  ··  ··  ··  2·8  1·8  ··  ··  ··  ··  ··  2·6   Larynx   3  70·6  70·8  73·2  0·0  0·8  0·2  74·9  ··  ··  ··  ··  ··  ··  ··   5  64·9  66·1  ··  0·3  ··  ··  70·4  ··  ··  ··  ··  ··  ·· Brain   3  16·3  16·0  15·9  -0·1  0·0  0·0  17·5  17·1  16·2  17·5  -0·2  0·4  -0·1  17·7   5  12·4  12·5  ··  0·0  ··  ··  14·0  13·9  13·4  ··  -0·1  ··  ··  14·2   5 (conditional) 40·3  40·0  ··  -0·1  ··  ··  40·2  47·9  43·7  ··  -1·0 ¶  ··  ··  48·1   10  7·9  ··  ··  ··  ··  ··  9·1  9·6  ··  ··  ··  ··  ··  9·7   Hodgkin's disease   3  86·7  85·0  84·2  -0·4  -0·2  -0·3 ¶  85·9  86·7  86·6  83·4  0·0  -1·1 ¶  -0·2  82·3   5  83·8  82·6  ··  -0·3  ··  ··  84·1  83·0  83·6  ··  0·1  ··  ··  77·7   5 (conditional) 91·1  91·5  ··  0·1  ··  ··  93·8  90·3  90·6  ··  0·1  ··  ··  89·1   10  80·0  ··  ··  ··  ··  ··  81·2  80·2  ··  ··  ··  ··  ·· Leukaemia   3  50·0  50·0  49·9  0·0  0·0  0·0  49·3  46·3  46·5  47·2  0·1  0·2  0·1  47·3   5  42·7  43·6  ··  0·2  ··  ··  42·7  40·3  41·7  ··  0·4  ··  ··  42·7   5 (conditional) 66·3  68·2  ··  0·5  ··  ··  69·1  66·1  70·5  ··  1·1 §  ··  ··  70·4   10  32·2  ··  ··  ··  ··  ··  33·8  32·7  ··  ··  ··  ··  ··  35·3   Wales   Oesophagus   3  12·4  16·5  14·4  1·0 ¶  -0·7  0·5 ¶  14·5  12·4  16·5  14·4  1·0 ¶  -0·7  0·5 ¶  14·3   5  10·8  11·7  ··  0·2  ··  ··  9·2  8·8  10·5  ··  0·4  ··  ··  12·2   5 (conditional) 34·3  30·5  ··  -0·9  ··  ··  21·1  32·6  31·1  ··  -0·4  ··  ··  34·3   10  7·5  ··  ··  ··  ··  ··  7·0  6·9  ··  ··  ··  ··  ··  8·9   Stomach   3  16·2  17·4  20·2  0·3  1·0  0·3  18·4  16·1  17·8  22·4  0·4  1·5  0·5 ¶  24·8   5  12·7  14·3  ··  0·4  ··  ··  16·0  12·9  15·3  ··  0·6  ··  ··  19·9   5 (conditional) 38·1  36·2  ··  -0·5  ··  ··  43·8  41·4  43·3  ··  0·5  ··  ··  55·4   10  11·2  ··  ··  ··  ··  ··  12·6  10·4  ··  ··  ··  ··  ··  15·4   Colon   3  51·7  54·4  56·3  0·7  0·6  0·5 ¶  56·7  49·4  53·3  52·5  1·0 ¶  -0·3  0·5 ¶  51·4   5  46·5  49·9  ··  0·9  ··  ··  51·7  44·1  47·8  ··  0·9 ¶  ··  ··  45·8   5 (conditional) 70·3  71·9  ··  0·4  ··  ··  73·5  68·6  71·2  ··  0·7  ··  ··  71·3   10  42·9  ··  ··  ··  ··  ··  45·0  40·5  ··  ··  ··  ··  ··  43·0   Rectum   3  52·8  57·9  58·0  1·3 ¶  0·0  0·7 ¶  58·0  56·7  58·7  62·0  0·5  1·1  0·5  58·9   5  46·4  48·5  ··  0·5  ··  ··  49·5  50·7  53·9  ··  0·8  ··  ··  56·3   5 (conditional) 63·6  62·0  ··  -0·4  ··  ··  64·7  68·1  71·2  ··  0·8  ··  ··  72·1   10  41·1  ··  ··  ··  ··  ··  42·6  44·6  ··  ··  ··  ··  ··  48·8   Pancreas   3  5·6  4·4  5·0  -0·3  0·2  -0·1  5·0  3·6  4·4  5·0  0·2  0·2  0·2  3·3   5  4·5  3·5  ··  -0·3  ··  ··  4·0  3·0  2·8  ··  -0·1  ··  ··  2·0   5 (conditional) 29·9  22·4  ··  -1·9  ··  ··  20·2  24·0  23·0  ··  -0·2  ··  ··  12·9   10  3·5  ··  ··  ··  ··  ··  3·1  2·4  ··  ··  ··  ··  ··  1·6   Larynx   3  65·7  67·2  64·6  0·4  -0·9  0·1  62·4  ··  ··  ··  ··  ··  ··  ··   5  60·3  63·4  ··  0·8  ··  ··  54·7  ··  ··  ··  ··  ··  ·· Myeloma   3  36·5  45·4  49·8  2·2 ¶  1·5  1·5 ¶  46·0  40·9  41·2  41·2  0·1  0·0  0·0  35·2   5  25·3  34·9  ··  2·4 ¶  ··  ··  36·8  27·4  27·6  ··  0·1  ··  ··  22·4   5 (conditional) 40·7  51·8  ··  2·8 ¶  ··  ··  51·2  43·2  44·9  ··  0·4  ··  ··  32·4   10  12·4  ··  ··  ··  ··  ··  20·7  14·1  ··  ··  ··  ··  ··  7·5   Leukaemia   3  45·5  47·4  46·2  0·5  -0·4  0·2  48·3  45·1  46·7  50·6  0·4  1·3  0·5  51·4   5  38·4  41·1  ··  0·7  ··  ··  45·3  38·5  41·0  ··  0·6  ··  ··  40·7   5 (conditional) 63·6  65·5  ··  0·5  ··  ··  69·1  70·2  66·7  ··  -0·9  ··  ··  63·3   10  27·8  ··  ··  ··  ··  ··  35·9  32·0  ··  ··  ··  ··  ··  33·4 All patients were adults aged 15-99 years, were diagnosed between 1996 and 2006 in England and Wales, and were followed up to 2007. *Mean annual change (%) in relative survival since previous calendar period. †Annual change (%) in relative survival over the three periods. ‡Survival predicted for patients diagnosed in 2007 using the hybrid approach (see text). §p<0·01. ¶p<0·05. ||Not enough data to be estimated. (table 4) . Even so, the funnel plots show that the South West region (fi gure 3, symbol K) was still a high-survival outlier in 2004-06, while the North West region (fi gure 3, symbol B) was still a low-survival outlier.
Very little regional variation in breast-cancer survival was seen in England, where 1-year survival was close to 95% for women diagnosed during 1996-2000 and 96% for those diagnosed in 2001-03, and 92% and 94%, respectively, in Wales (table 4) Survival in the North West (fi gure 3, symbol B) is lower than the pooled English value: the diff erence is small, but the value is below the 99·8% control limits, and the downward annual trend during 2004-06 is outside the control limit. 1-year survival in Wales (fi gure 3, symbol W) during 2004-06 was also below the control limits, but the year-on-year trend during that period was positive, and within the control limits.
Despite gradual improvement, 1-year relative survival from lung cancer remains poor, around 27% for men diagnosed during 2004-06 (table 4) . 1-year survival in the Yorkshire and Humber region (fi gure 3, symbol D) and Wales (fi gure 3, symbol W) was below the lower 95% control limit in that period, whereas survival in the London region (fi gure 3, symbol H) was above the upper limit. Again, the annual trend in the North West region (fi gure 3, symbol B) during 2004-06 was just below the lower 95% control limit, whereas the trend in the West Midland region (fi gure 3, symbol F) was above the upper limit.
Discussion
Cancer survival, especially at 1 year after diagnosis, improved for most of the 21 cancers examined, both in England and Wales, during the period 1996-2007. Two distinct groups of cancers emerge from this analysis. The fi rst group, with a generally poor prognosis, consists of fi ve cancers for which 1-year survival is often below 40% in men and women: cancers of the oesophagus, stomach, pancreas, lung, and brain. Survival from cancers of the pancreas and lung has hardly improved at all between 1996-2007, and 1-year survival for pancreatic cancer remains below 20%. For the 25 remaining cancer-sex combinations, short-term prognosis is moderate or good, with 1-year survival over 60%. The gap of 20% or more in 1-year survival between these two groups of cancers is striking and persistent. The range of survival in the group of cancers with higher survival has tended to narrow over time, because of a ceiling eff ect among malignancies for which 1-year survival is already 90% or higher: melanoma of the skin and cancers of the breast, uterus, prostate, and testis, and in England only, Hodgkin's disease. Part of the increase in survival for prostate cancer may be attributable to the diagnosis of more indolent tumours as a result of widespread prostate-specifi c antigen (PSA) testing.
A key aim of the NHS cancer plan for England, published in September, 2000, was to improve the prospects of survival for cancer patients. This study examines survival trends for 21 common cancers in England and Wales up to 2007. The availability of 6 years of data on incident cancers in both England and Wales since the publication of the cancer plan provided an early opportunity to examine its eff ect. The nearest equivalent cancer strategy for Wales, Designed to Tackle Cancer, 5 was not published until December, 2006, so survival trends in Wales off er an interesting comparison with trends in England. 
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The survival estimates reported here are not agestandardised because the age distribution of cancer patients was fairly stable for most cancers during this short period (11 years). Age-standardised survival analyses showed almost no eff ect on the estimation of survival or trends in survival (data not shown). A notable exception was Hodgkin's disease, for which the marked fall in survival during 2004-06 was partly due to an increase in the age at diagnosis of patients diagnosed with this malignancy: the mean age at diagnosis increased by about 3 years between 1998 and 2005. Incidence of the 21 cancers examined was generally stable over the period 1996-2006, except for a rise in cancers of the prostate and breast, and melanoma of the skin, and a fall in cancers of the lung and stomach in men. Recorded incidence and survival have fallen for bladder cancer in England, but not in Wales (fi gure 2). The fall in survival in England is mainly attributable to progressive change in the recorded spectrum of urothelial malignancies, following changes in pathological classifi cation and coding 34 that have not yet occurred to the same extent in Wales.
Patients who had previously had a primary malignancy in a diff erent organ or tissue were included in these analyses, by contrast with our previous work. 23, 35 This was done mainly because of the marked increase of asymptomatic prostate cancer detected by PSA, since these men have extremely high survival, which would artifi cially raise the proportion of patients excluded for a previous primary cancer. Survival estimates were virtually identical with and without the exclusion of patients with more than one tumour (data not shown).
In the past, patients who died on the date of diagnosis could not be distinguished in the national cancer registry data from DCO registrations, for which the true duration of survival is unknown. 9 A fl ag to indicate DCO status is now available for more than 90% of cancers registered since 1996 in England and Wales, but we excluded both DCO registrations and other cases with zero recorded survival, for consistency with most other publications on cancer survival. Inclusion of those patients who do appear to have died on the same day as the diagnosis (no DCO fl ag) would have reduced the estimates of 1-year survival for some cancers by up to 1%, but it had no eff ect on the estimated trends in survival (data not shown).
Successive EUROCARE studies have shown that cancer survival in both England and Wales has lagged behind other countries in western and northern Europe, despite encouraging recent results showing that both countries have tended to approach the levels of survival in other European countries during 1995-2002. 36 The EUROCARE studies formed part of the impetus to create the NHS cancer plan.
2 A recent editorial 37 questioned whether the UK really has an eff ective cancer plan, on the basis of fi ndings in the EUROCARE-4 study, 36 which included patients diagnosed up to 2002. Results from EUROCARE are in agreement with our own fi ndings, particularly for cancers of moderate and good prognosis. However, the NHS cancer plan only dates from 2000, so the EUROCARE-4 study cannot off er a fully viable European comparison of survival trends after its implementation.
1-year survival is the only cohort-based measure of outcome that is available for the whole period up to 2006. Even 3-year survival can only be estimated for patients diagnosed during 2004-06 by using the complete approach, and no estimation of 5-year survival for 2004-06 is currently possible without using the hybrid approach to incorporate follow-up data for patients who were diagnosed (and whose treatment will have begun) in earlier periods (fi gure 1). 1-year survival is nevertheless a valuable public-health measure. International diff erences 38 and, in England and Wales, socioeconomic diff erences 23 in 5-year survival are largely attributable to higher cancer-related mortality soon after diagnosis.
The data analysed here represent the earliest period from which an overall assessment of survival trends after implementation of the cancer plan could reasonably be attempted. Recent survival trends in England, more favourable than those in Wales, do indicate that the NHS cancer plan is having some benefi cial eff ect in England.
Our fi ndings do not, however, provide a defi nitive verdict on the overall eff ectiveness of the cancer plan.
The national data include over 2 million cancer patients and they are remarkably up to date, with follow-up data available to Dec 31, 2007 . But even with a large and timely dataset, and the latest techniques to assess recent survival trends, it seems we will need at least 3 years of follow-up data for all patients diagnosed during the period 2004-06, up to the end of 2009. The fi ndings also need to be extended for a longer period after the implementation of the cancer plan (patients diagnosed in 2007 or later). Future survival analyses for Wales should also provide further information on the overall effi cacy of cancer plans. Scotland implemented a strategic cancer plan in 2001, 39 while Northern Ireland has not yet done so. Incorporation of survival trends in Scotland and Northern Ireland in the same analytical strategy might improve the evaluation of national cancer plans in the UK.
Finally, it is essential to do more detailed analyses to investigate the eff ect on time trends and regional inequalities in cancer survival of some of the more specifi c measures listed in the cancer plan and the Cancer Reform Strategy, 40 such as MDTs, shorter waiting times for investigation and treatment, and the training and specialisation of surgeons and other specialists. Such studies will require more prompt and effi cient linkage of the national cancer data-and linkage to a wider range of health datasets-than is currently possible, as well as new ways of using this information to improve health policy.
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